abemaciclib Verzenio
Selected indexed studies
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). (J Clin Oncol, 2020) [PMID:32954927]
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. (N Engl J Med, 2025) [PMID:39660834]
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. (J Clin Oncol, 2025) [PMID:39693591]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. (2024) pubmed
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (2017) pubmed
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). (2020) pubmed
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. (2017) pubmed
- Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. (2025) pubmed
- Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. (2023) pubmed
- Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. (2025) pubmed
- Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. (2024) pubmed
- Overall survival with abemaciclib in early breast cancer. (2026) pubmed
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. (2021) pubmed